Ibuprofen reduces cell proliferation through inhibiting Wnt/β catenin signaling pathway in gastric cancer stem cells

Akrami, Hassan; Moradi, Behrouz; Farahani, Diba Borzabadi; Mehdizadeh, Kiumars

doi:10.1002/cbin.10959

Cited by 43 publications

(36 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is emerging evidence that ibuprofen may in certain specific situations act as an endocrine disrupter [118,119]. The role of ibuprofen in cancer is currently being discussed in the literature, because ibuprofen offers antiproliferative benefits in some situations [120][121][122]. Thus, the discussion about infection and ibuprofen is not surprising as we continue to learn more about this molecule in specific settings with specific patient populations.…”

Section: Discussionmentioning

confidence: 99%

Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review

Varrassi¹,

et al. 2019

View full text Add to dashboard Cite

Ibuprofen first came to market about 50 years ago and rapidly moved to over-thecounter (OTC) sales. In April 2019, the National Agency for the Safety of Medicines and Health Products (ANSM) of France issued a warning for NSAID uses by patients with infectious diseases based on an analysis of 20 years of real-world safety data on ibuprofen and ketoprofen. Nevertheless, ibuprofen remains a mainstay in the analgesic armamentarium and with numerous randomized clinical trials, head-to-head studies, and decades of clinical experience. The authors offer a review of the safety of ibuprofen and how it may differ from other NSAIDs. Ibuprofen is associated with certain well-known gastrointestinal adverse effects that are related to dose and patient population. Among nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen has a comparatively low risk of cardiovascular adverse effects. It has been associated with renal and hepatic adverse effects, which appear to depend on dose, concomitant medications, and patient population. The association of ibuprofen with infections is more complex in that it confers risk in some situations but benefits in others, the latter in cystic fibrosis. Emerging interest in the literature is providing evidence of the role of ibuprofen as a possible endocrine disrupter as well as its potential antiproliferative effects for cancer cells. Taken altogether, ibuprofen has a favorable safety profile and is an effective analgesic for many acute and chronic pain conditions, although it-like other NSAIDs-is not without risk. After 50 years, evidence is still emerging about ibuprofen and its unique safety profile among NSAIDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review

Varrassi¹,

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[36] In the A2780 cell line, ac oncentration of 100 mm for the [Ibu]-ILs and precursor salts was chosen due to the effect of ibupro-fen on the WNT/b-catenin pathway that affects the proliferation of these cells. [37][38][39][40] With the exception of [C 16 Pyr][Ibu] for both cell lines and [N 1,1,2,2OH1 ][Ibu] for A2780 tumorc ells, no cytotoxic effect was observed when exposed for 48 ht oe ach compound (in comparison with Na[Ibu]; Figure 2). Interestingly, for both cell lines, the cytotoxicity of [C 16 Pyr][Ibu] might be attributed to its cation, as [C 16 Pyr]Cl displayed IC 50 values of < 100 and 2.2 AE 0.1 mm for fibroblasts andA 2780 cells, respectively ( Figure 2A and Table 2).…”

Section: ) Melting (T M ) Crystallization (T C ) and Cold Crystallmentioning

confidence: 99%

Ionic Liquids and Salts from Ibuprofen as Promising Innovative Formulations of an Old Drug

et al. 2019

View full text Add to dashboard Cite

Herein we report the synthesis of novel ionic liquids( ILs) and organic salts by combining ibuprofen as anion with ammonium, imidazolium, or pyridinium cations. The methodology consists of an acid-base reactiono fn eutral ibuprofen with cation hydroxides, which were previouslyp repared by anion exchange from the correspondingh alide salts with Amberlyst A-26(OH). In comparison with the parent drug, these organic salts display higher solubility in water and biological fluids and as maller degree of polymorphism, which in some cases was completely eliminated. With the exceptiono f [ C 16 Pyr][Ibu] and [N 1,1,2,2OH1 ][Ibu],t he prepared salts did not affect the viabilityo f normalh uman dermalf ibroblasts or ovarian carcinoma (A2780) cells. Therefore, these ibuprofen-based ionic liquids may be very promising lead candidates for the development of effective formulationso ft his drug.Ibuprofen is used in the treatmento fp aina nd inflammation in rheumatoid arthritisa nd other musculoskeletal disorders in both humans and animals. [1] It is considered one of the Essential Medicines by the World Health Organization( WHO). Ibuprofen is an onsteroidal anti-inflammatory drug (NSAID), which nonselectively inhibits cyclooxygenases 1a nd 2( COX-1a nd COX-2), resulting in the inhibition of prostaglandins. [2] Althoughi th as as trongera nalgesice ffect than other NSAIDs in some types of pain, [3] the mean onset of action per 400 mg dose is 45 minutes, which can be critical in an acute painsituation, where rapid relief is critical. [4] Its low solubility in the acidic aqueous media of the stomach is responsible for ibuprofen'ss low pharmaceutical effect, [5] despite its ease of permeability through the gastrointestinal membranes, rendering close to 100 %b ioavailability. [6] To increase the absorption rate and to provide faster pain relief, new formulations of ibuprofen have been developed over the years, particularly salts (sodium, [7] lysine, [8] and arginine [9] )a nd extrudate. [10] These forms, however,d on ot tackle the degree of ibuprofen's poly-morphism, [11] whose different crystal shapes display distinct pharmaceutical effects.For the last 10 years, ionic liquids (ILs) from active pharmaceuticali ngredients (APIs), or simply API-ILs, have been studied at the academic level, as the third generation of ILs. [12][13][14][15] ILs are salts with meltingt emperatures below 100 8C, with some of them being liquid at room temperature (RTILs), that result from the combinationoforganic cations with organic and inorganic anions. The scope of their physicala nd chemical properties has promptedt he study and application of these compounds in several areas of science and technology. [16] In the field of pharmaceutical sciences,w ea nd others have reported that the cation-anion interactions in the prepared API-ILs induce improved physicochemical properties over the original drugs, decrease toxicityt oward healthyc ells, and thus render potentially enhanced pharmaceutical activity to the API. [17][18][19][20][21][22] In more detail,s u...

show abstract

“…CASK, which has been intensively studied in neurons, is deemed to be an important histone protein in cortical networks and may be involved in the establishment and maintenance of synaptic connections [41][42][43][44]. The role of CASK in carcinoma has been reported only in oesophageal cancer, gastric cancer and colorectal cancer [45,46]. Wang et al found that CASK expression in oesophageal cancer was upregulated at the mRNA and protein levels [39].…”

Section: Discussionmentioning

confidence: 99%

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Gao

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Cholangiocarcinoma (CCA) is an invasive malignancy arising from biliary epithelial cells; it is the most common primary tumour of the bile tract and has a poor prognosis. The aim of this study was to screen prognostic biomarkers for CCA by integrated multiomics analysis. Methods: The GSE32225 dataset was derived from the Gene Expression Omnibus (GEO) database and comprehensively analysed by using R software and The Cancer Genome Atlas (TCGA) database to obtain the differentially expressed RNAs (DERNAs) associated with CCA prognosis. Quantitative isobaric tags for relative and absolute quantification (iTRAQ) proteomics was used to screen differentially expressed proteins (DEPs) between CCA and nontumour tissues. Through integrated analysis of DERNA and DEP data, we obtained candidate proteins APOF, ITGAV and CASK, and immunohistochemistry was used to detect the expression of these proteins in CCA. The relationship between CASK expression and CCA prognosis was further analysed. Results: Through bioinformatics analysis, 875 DERNAs were identified, of which 10 were associated with the prognosis of the CCA patients. A total of 487 DEPs were obtained by using the iTRAQ technique. Comprehensive analysis of multiomics data showed that CASK, ITGAV and APOF expression at both the mRNA and protein levels were different in CCA compared with nontumour tissues. CASK was found to be expressed in the cytoplasm and nucleus of CCA cells in 38 (45%) of 84 patients with CCA. Our results suggested that patients with positive CASK expression had significantly better overall survival (OS) and recurrence-free survival (RFS) than those with negative CASK expression. Univariate and multivariate analyses demonstrated that negative expression of CASK was a significantly independent risk factor for OS and RFS in CCA patients. Conclusions: CASK may be a tumour suppressor; its low expression is an independent risk factor for a poor prognosis in CCA patients, and so it could be used as a clinically valuable prognostic marker.

show abstract

Ibuprofen reduces cell proliferation through inhibiting Wnt/β catenin signaling pathway in gastric cancer stem cells

Cited by 43 publications

References 43 publications

Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review

Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review

Ionic Liquids and Salts from Ibuprofen as Promising Innovative Formulations of an Old Drug

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Contact Info

Product

Resources

About